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Diet-induced  obesity  (DIO)  causes  tau  phosphorylation  in  wild-type  mouse  hippocampus.
DIO  enhances  astrogliosis,  astroglial  leptin  receptor  expression,  and mild  microgliosis.
Astroglial  leptin  receptor  may  play  a role  in  these  pathological  processes.
Voluntary  exercise  can  prevent  these  DIO-induced  pathological  changes.
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Accumulating  evidence  indicates  that  obesity  is an  independent  risk  factor  for  developing  Alzheimer  dis-
ease (AD).  Recent  studies  have  shown  that  diet-induced  obesity  (DIO) enhances  AD-related  pathologies
in  transgenic  mouse  models  of  the  disease.  DIO  increases  amyloid   (A)  deposition  in  amyloidogenic
transgenic  mice  and  enhances  tau phosphorylation  in  tau transgenic  mice.  However,  it remains  unclear
whether  DIO  also  enhances  AD-related  pathological  processes  in  wild-type  (WT)  mice.  In this  study,
we  examined  the  effects  of DIO  on  A  and  tau pathology  in  WT  mice  using immunohistochemistry.
In  addition,  we  evaluated  the  protective  effect  of  voluntary  exercise  on  the  DIO-induced  pathological
changes.  DIO  caused  tau  phosphorylation  and  astroglial  activation  in  the hippocampus  in WT mice.  Inter-
estingly,  these  changes  were  associated  with  enhanced  astrocytic  leptin  receptor  (LepR)  expression  and
mild microgliosis,  but  not  A  accumulation.  Although  phosphorylated  tau staining  was  only  observed
in  the hippocampus,  astrogliosis  and microgliosis  were  present  in  both  the  amygdala  and  hippocampus.oluntary exercise However,  no apparent  neuronal  loss  was  observed.  Voluntary  exercise  prevented  these  DIO-induced
pathological  changes.  Our  results  demonstrate  for the ﬁrst  time  that DIO causes  tau  phosphorylation
and that  astrocytic  LepR  might  be  involved  in  the pathological  process  in  WT  mouse  hippocampus.  Our
ﬁndings  also suggest  that  physical  exercise  is  a promising  strategy  for the  prevention  of AD in patients
with  obesity.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CCAbbreviations: AD, Alzheimer disease; DIO, diet-induced obesity; A, amyloid
;  WT,  wild-type; LepR, leptin receptor; GFAP, glial ﬁbrillary acidic protein; LepRs,
hort form of leptin receptor; LepRl, long form of leptin receptor.
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1. Introduction
Alzheimer disease (AD) is the most common cause of demen-
tia, with the number of patients increasing steadily worldwide
[5]. Accumulating evidence indicates that obesity raises the risk
of developing AD, independent of other factors [6,17,20]. Conse-
quently, the risk of developing AD may  be decreased by reducing
obesity, a preventable disease. However, little is known about
the causative link between obesity and AD. AD is pathologically
characterized by the extracellular deposition of amyloid  (A)
as senile plaques, as well as the intracellular accumulation of
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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yperphosphorylated aggregated tau in the form of neuroﬁbrillary
angles [8]. Recent studies have shown that diet-induced obesity
DIO) enhances AD-related pathology in transgenic mouse models
f AD. DIO increases A deposition and memory deﬁcits in APPSWE
ransgenic mice expressing human APP695 containing the Swedish
ouble mutation (KM670/671NL) [14,15]. DIO also exacerbates tau
hosphorylation in the hippocampus and impairs learning abil-
ty in tau transgenic mice [12]. These studies clearly show that
IO accelerates AD-associated pathological processes and dimin-
shes cognitive function. Furthermore, APPSWE transgenic mice fed
 high-fat diet and given physical exercise show less A deposition
han their counterparts fed a high-fat diet without physical exercise
14,15]. These ﬁndings indicate that physical exercise can prevent
besity-induced pathological changes in AD mouse models. Addi-
ionally, in WT  rats, DIO increases glial ﬁbrillary acidic protein
GFAP) expression in the hippocampus [7] and impairs cognitive
unction [11]. However, it remains unclear whether DIO enhances
D-related pathological processes in WT mice.
The purpose of this study was to examine the effects of DIO on
au pathology using immunohistochemistry in WT  mice. We  also
ssessed the protective effect of voluntary exercise on the patho-
ogical changes induced by DIO.
. Material and methods
WT  female mice (B6C3H/F1) were divided into high calorie diet
Fat = 15.3%; 4.15 Cal/g, Quick Fat (Clea Japan Inc., Tokyo, Japan))-
ed (n = 21) and standard diet (Fat = 4.5%; 3.3 Cal/g)-fed (SD, n = 6)
roups. The high calorie diet group was subdivided into no-exercise
HCD, n = 17) and exercise (HCD + Ex, n = 4) groups. Mice in the HCD
nd HCD + Ex groups were fed a high calorie diet, starting at the age
f 12 weeks. HCD + Ex group mice were housed in cages equipped
ith a running wheel (Clea Japan Inc., Japan) for voluntary exer-
ise from the age of 8 weeks. The average amount of exercise was
.1 ± 0.4 × 104 rounds/day (≈7.4 ± 2.5 km/day, mean ± SD). Body
eight was measured every 4 weeks. Animals were anesthetized
y intraperitoneal injection of 1% xylocaine at the age of 40 weeks
nd decapitated. The body temperature was controlled during the
nesthesia using a heating pad. We  used PS19 tauopathy model
ice, which carry the human tau gene with a P301S mutation [21],
s positive controls for evaluating tau pathology. In all experiments,
e used only female mice because there was a large difference in
ody weight between male and female, and the body weight of
ale mice varied much more widely than that of female mice in a
reliminary experiment.
Intraperitoneal glucose tolerance tests (IGTTs) were performed
t 40 weeks of age. On the night before the IGTTs, food was removed
t 6:00 PM,  and the following morning, mice were given a single
ose, by intraperitoneal injection, of glucose (2 g/kg body weight).
lood samples were collected from the tail vein immediately before
lucose administration and at 15, 30, 60 and 120 min  after gavage.
lood glycemic content was assessed using Glutest Ace R (Sanwa
agaku Kenkyusho Co., Ltd, Nagoya, Japan), following the manu-
acturer’s instructions. For analyses, glucose responses over time
ere integrated to determine the area-under-the-curve.
Tissue preparation and immunohistochemical analysis were
erformed as previously described [21]. Brieﬂy, mice were deeply
nesthetized and transcardially perfused with 15 ml  phosphate-
uffered saline (PBS). The brains were removed, immersion-ﬁxed
or 24 h in 4% paraformaldehyde/PBS, and stored in 15% sucrose/PBS
t 4 ◦C until use. The brains were cut into 20-m-thick sections
or immunohistochemical analysis. Free-ﬂoating sections were
mmunostained using streptavidin-biotin peroxidase.
The following antibodies were used in this study: mAb
T8 (1:100; Innogenetics, Gent, Belgium), mAb  AT180 (1:100;tters 571 (2014) 11–16
Innogenetics), mAb  S422 (1:100; Invitrogen, CA, USA), anti-glial ﬁb-
rillary acidic protein (1:1000; Dako, CA, USA), anti-Iba-1 (1:1000;
Wako, Osaka, Japan), anti-leptin receptor M18  (1:100; Santa Cruz
Biotechnology, CA, USA), and anti-leptin receptor C14104 (1:100;
Neuromics, MN,  USA).
Images were captured with a Nikon eclipse 80i microscope and
a Nikon DXM 1200C digital camera. To measure the area occupied
by S422-, GFAP-, Iba-1- and M18-positive cells in the hippocam-
pus and amygdala we obtained three images each of the CA1, CA3
and dentate gyrus regions of the hippocampus and ﬁve images
each of the amygdala for each animal. The quantiﬁcation of the
positively labeled areas was performed using Photoshop (Adobe
Systems, CA, USA). The number of neurons and the number of
GFAP- and Iba-1 positive cells were measured manually using dig-
ital photomicrographs. Quantiﬁcation results were analyzed using
one-way ANOVA, followed by Tukey’s post hoc test or Scheffe’s post
hoc test. Results were expressed as mean ± SD, and differences with
P < 0.05 were considered signiﬁcant.
3. Results
To evaluate the effect of diet and exercise, we measured body
weight gain every 4 weeks. After 20 weeks of age, the body weight
of HCD mice was signiﬁcantly increased compared with SD mice
or HCD + Ex mice (Fig. 1A). To estimate glucose tolerance, we per-
formed IGTTs on the three groups. Although serum glucose at
60 min  was slightly elevated in the HCD group compared with the
SD or HCD + Ex group, the area-under-the-curve was  not signiﬁ-
cantly different among the three groups (Fig. 1B). These ﬁndings
suggest that glucose metabolism is not signiﬁcantly perturbed in
HCD mice.
To assess the effect of DIO on the tau phosphorylation, the
neuropathological hallmarks of AD, we  performed immunohisto-
chemistry using several phosphorylation-speciﬁc tau antibodies;
S422 (phospho-Ser422), AT-8 (phospho-Ser202 and phospho-
Thr205) and AT-180 (phospho-Thr231). Sections from the three
different groups in WT  mice were not labeled with AT-8 (Fig. 1C)
or AT-180 (Fig. 1D). Interestingly, dendrites in the CA1 region and
mossy ﬁber in the CA3 region were slightly stained with S422 in
HCD mice (Fig. 1G and H), but not in SD (Fig. 1E and F) or HCD + Ex
(Fig. 1I and J) mice. As positive controls, perikarya and neurites
in the CA1 of the hippocampus from the 24-week-old PS19 mice
were strongly stained with AT-8 (Fig. 1C, inset), AT-180 (Fig. 1D,
inset), or S422 (Fig. 1E, inset), respectively. Quantitative analysis
revealed that the percentage of the area occupied by S422-positive
cells is higher in HCD mice than in SD or HCD + Ex mice (Fig. 1K).
We also examined the amygdala and other brain regions, but they
were not stained with S422, AT-8 or AT-180. It is known that tau
phosphorylation occurs in neurites in early phase [18]. From these
results, we  conjectured that DIO can at least partially induce tau
phosphorylation in the hippocampus in WT  mice. Next, to assess
neurodegeneration, we  counted the number of neurons in the hip-
pocampus. The number of neurons in the hippocampus was  not
signiﬁcantly different among the three different groups (data not
shown), suggesting that neurodegeneration was  not present.
Because astrogliosis parallels the distribution of tau phos-
phorylation in neurodegenerative diseases [2,19], we performed
immunohistochemistry with an antibody to GFAP. The number of
GFAP-immunoreactive astrocytes in the CA1 and CA3 regions of the
hippocampus was signiﬁcantly increased (Fig. 2B and E) and some
astrocytes displayed hypertrophic changes (Fig. 2B, E, inset) in HCD
mice compared with SD (Fig. 2A and D) or HCD + Ex mice (Fig. 2C
and F). Similar changes were observed in the amygdala (Fig. 2G–I).
Quantitative analysis revealed that the percentage of the area occu-
pied by GFAP-positive cells (Fig. 2P) and the number of astrocytes
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Fig. 1. Effects of a high calorie diet and voluntary exercise on body weight and glucose tolerance (A and B). Graphs show the change in body weight every 4 weeks (A) and
the  glucose tolerance test results at the age of 40 weeks (B). Immunohistochemistry for AT-8, AT-180-, or Ser422-phosphorylated tau in the hippocampus (C–J). Sections
from  CA1 region of the hippocampus in the HCD group mice are not stained with AT-8 (C) or AT-180 (against pThr231) (D) antibodies and counterstained with hematoxylin.
The  CA1 and CA3 regions of the hippocampus from SD (E and F), HCD (G and H) and HCD + Ex (I and J) mice are stained S422 antibody (against pSer422). Dendrites in the CA1
region  (E) and mossy ﬁber in the CA3 region (F) are stained with S422 in HCD mice, but not in SD or HCD + Ex mice. Perikarya and neurites in the CA1 of the hippocampus
from  the 24-week-old PS19 mice were strongly stained with AT-8 (C, inset), AT-180 (D, inset), or S422 (E, inset), respectively. The graph shows that the area of S422 positive
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Fig. 2Q) were increased in the hippocampus and amygdala of HCD
ice compared with SD or HCD + Ex animals. Because microglia-
ediated neuroinﬂammation is implicated in the pathogenesis of
eurodegenerative diseases [1,21–23], we assessed microglial acti-
ation using an anti-Iba-1 antibody. In HCD mice, the number of
icroglia was  increased in the hippocampus (Fig. 2J–L) and the
mygdala (Fig. 2M–O), paralleling the distribution of astrogliosis.
lthough signiﬁcant microglial morphological differences were not
een among the three different groups (Fig. 2J–O, inset), the per-
entage of the area occupied by Iba-1-positive cells (Fig. 2R) and the
umber of microglia (Fig. 2S) were increased in the hippocampus
nd amygdala of HCD mice compared with SD or HCD + Ex ani-
als. These ﬁndings of increased astrogliosis and microgliosis in the
bsence of neuronal loss suggest that the activation of astrocytes
nd microglia in HCD mice is not secondary to the neurodegenera-
ive changes, but might be directly caused by DIO. The results also
ndicate that microglial activation is relatively mild compared with
stroglial activation.
As described above, we observed tau phosphorylation and
strogliosis in the HCD mouse hippocampus. Our previous study
sing PS19 mice showed that DIO enhanced tauopathy and neu-
oinﬂammation through the activation of astrocytic leptin receptor
LepR) (Unpublished data). Therefore, focusing on the role of lep-
in receptor in the WT  mice, we performed immunohistochemistry
or LepR in the hippocampus where the overt astrogliosis occurred.
epR can be divided into two isoforms; long form (LepRl) and
hort form (LepRs). We  used anti-M18 antibody, which recognizesta are mean ± SD. *P < 0.05, HCD vs. SD or HCD + Ex mice. **P < 0.01, HCD vs. SD or
the short cytoplasmic form of membrane-bound LepR [9]. M18-
positive cells were seen mainly in the hippocampus (Fig. 3A–C) and
the hypothalamus (data not shown). M18-positive cells were con-
sidered astrocytes on a morphological basis, and double-labeled
hippocampal sections demonstrated that all M18-expressed cells
were GFAP-positive astrocytes (Fig. 3D–F). To quantify the LepRs
expression, we  standardized the M18-positive area divided by the
GFAP-positive area because LepRs was expressed in astrocytes and
HCD increased the area of astrocytes. As shown in Fig. 3G, the
expression of astrocytic LepRs was signiﬁcantly increased in the
hippocampus of HCD mice compared with SD or HCD + Ex ani-
mals. This indicated that DIO caused not only astrogliosis, but also
increase expression of LepRs. We  also performed immunohisto-
chemistry with a CH14104 antibody, which recognizes the unique
LepRl cytoplasmic tail sequence, but staining was  barely visible in
the hippocampus (data not shown).
4. Discussion
Our results demonstrate that persistent obesity from early life
induces tau phosphorylation in the hippocampus accompanied
by enhanced astroglial LepRs expression, which might be directly
related to obesity. Although phosphorylated tau staining was only
seen in the hippocampus, astroglial activation and microgliosis
were seen in the amygdala and hippocampus, both regions in which
tau pathology is preferentially seen in AD. The difference in distri-
bution suggests that astroglial activation and microgliosis might
14 S. Koga et al. / Neuroscience Letters 571 (2014) 11–16
Fig. 2. Immunohistochemistry for GFAP and Iba-1 in the hippocampus and amygdala. The CA1 (A–C and J–L) and CA3 (D–F) regions of the hippocampus and amygdala (G–I
and  M–O) from SD (A, D, G, J and M),  HCD (B, E, H, K and N) and HCD + Ex (C, F, I, L and O) mice were stained for GFAP (A–I) or Iba-1 (J–O). HCD mice show marked expression
of  GFAP in the hippocampus (B and E) and amygdala (H). Some astrocytes in HCD animals show hypertrophic changes (B, E, H, inset). HCD mice have an increased number of
microglia in the hippocampus (K) and the amygdala (N); however, morphological differences between the three different groups were not observed (J–O, inset). The graphs
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recede tau phosphorylation. Because there was no evidence of
eurodegeneration in the hippocampus even though tau phosphor-
lation was observed in this region, obesity itself may not induce
he entire pathological process of tau-phosphorylation-related
eurodegeneration or might require a much longer period of time
o induce neurodegeneration. In this study, tau phosphorylation
as observed only at Ser422, but not at Ser202/Thr205. There is a
onsistent pattern of tau phosphorylation that corresponds to the
egree of neuronal cytopathology during neuroﬁbrillary tangle for-
ation [3]. Ser422 is phosphorylated earlier than Ser202/Thr205,
hich is recognized by AT-8 [3]. In addition, tau phosphorylation
s detected in neurites earlier than in cell body in early phase [18].
herefore, we presumably observed one of the earliest tau patho-
ogical changes.
Recently, Jayaram et al. that reported that DIO did not increase
FAP expression in astrocyte-speciﬁc LepR knockout mice; rather,
t reduced [10]. Although they did not mention the isoform of astro-
ytic LepR, our study showed that LepRs, not LepRl, was  expressed
n astrocytes. Therefore, astrocytic LepRs is thought to be involved
n the process of DIO-induced astrogliosis. Furthermore, a recent
tudy showed that the LepRs functions as a proinﬂammatory fac-
or during leptin resistance [13]. Thus, our results suggest that
IO might enhance astroglial leptin sensitivity and activation by
p-regulating the LepRs, which in turn might promote tau phos-
horylation by enhanced inﬂammatory responses. However, the
ink between astroglial activation, enhanced LepRs expression and
nﬂammation remains unclear and requires further investigation.
Recent studies have shown differing results on whether DIO
nhances tau phosphorylation in WT  mice [4,12,16]. Both Moroz’s) or microglia (S) in the hippocampus and amygdala are greater in HCD mice than
 < 0.01, HCD vs. SD or HCD + Ex mice.
study (60%-fat chow, fed for 4 months from 1 month of age) and
Leboucher’s study (59%-fat chow, fed for 5 months from 2 months of
age) reported that DIO increased the level of tau but did not induce
tau phosphorylation [12,16]. On the other hand, Bhat’s study (21%-
fat chow, fed for 2 months from 4 months of age) and our present
study (15.3%-fat chow, fed for 7 months from 3 months of age)
showed that DIO increased tau phosphorylation in WT mice [4].
The discrepancy in results probably arises from food nutrition, feed-
ing duration, or both. Interestingly, studies feeding mice a mildly
high-fat diet demonstrated tau phosphorylation. We  therefore con-
jecture that DIO itself can promote a subset of tau phosphorylation
but depends on conditions which remain unclear.
Some studies have shown that physical exercise alleviates
pathological changes elicited by DIO in the AD model without
reduction in body weight [14,15]. Our results in WT mice are in line
with the ﬁndings in these reports; voluntary exercise inhibits DIO-
induced tau phosphorylation, astroglial activation and microgliosis
in the hippocampus. However, it remains unclear whether vol-
untary exercise directly alleviates these pathological changes in
this study because the body weight of mice in the HCD + Ex group
was signiﬁcantly lower than that of mice in the HCD group. More-
over, HCD mice showed slight glucose intolerance and voluntary
exercise mitigated the change. It is possible that improvement of
obesity and/or glucose intolerance ameliorated these pathological
changes.In conclusion, the present study demonstrates that DIO at least
partially causes tau phosphorylation and that astrocytic LepRs
may play a role in the pathogenetic process in WT  mouse hip-
pocampus. While obesity itself does not appear to directly cause
S. Koga et al. / Neuroscience Letters 571 (2014) 11–16 15
Fig. 3. Immunohistochemistry for M18  in the hippocampus. The CA1 regions of the hippocampus from SD (A), HCD (B) and HCD + Ex (C) mice were stained for M18
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han  in the SD or HCD + Ex groups (G). Scale bars: 50 m (A–F). Data are mean ± SD
eurodegeneration, it might accelerate pathological processes in
eurodegenerative disorders. Our ﬁndings also indicate that phys-
cal exercise might be a promising strategy for the prevention of
D in patients with obesity.
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